What is Veracyte's EV / sales?

Veracyte (VCYT) reported EV / sales of 4.3× in Q1 2026.

How has Veracyte's EV / sales changed year-over-year?

Veracyte's EV / sales decreased by 8.2% year-over-year, from 4.7× to 4.3×.

What is the long-term trend for Veracyte's EV / sales?

Over 5 years (2020 to 2025), Veracyte's EV / sales has grown at a -26.3% compound annual growth rate (CAGR), from 26.7× to 5.8×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Veracyte VCYT EV / sales

EV / sales at other companies

Guardant HealthGH

11.8×+4.3×

Natera, Inc.NTRA

11×+1.0×

Bio-Rad LaboratoriesBIO

3.1×+0.1×

RevvityRVTY

4.4×-0.9×

Labcorp HoldingsLH

2×+0.1×

Quest DiagnosticsDGX

2.4×0.0×

Other financials

Income statement

See full

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

See full

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

See full

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

See full

Market cap$4.29B+10.7%

Profitability

See full

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

See full

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

enterprise value/total revenue=4.3×

Based on the most recent quarter.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veracyte's EV / sales?: Veracyte (VCYT) reported EV / sales of 4.3× in Q1 2026.
How has Veracyte's EV / sales changed year-over-year?: Veracyte's EV / sales decreased by 8.2% year-over-year, from 4.7× to 4.3×.
What is the long-term trend for Veracyte's EV / sales?: Over 5 years (2020 to 2025), Veracyte's EV / sales has grown at a -26.3% compound annual growth rate (CAGR), from 26.7× to 5.8×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.